Biotech News

Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology

Karyopharm Therapeutics (KPTI)Karyopharm Therapeutics2026-06-25 13:46 ESTClinical readout

KPTI (KPTI) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is kpti.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

KPTIKaryopharm Therapeutics2026-06-25 13:46 EST

Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026

KPTIKaryopharm Therapeutics2026-06-25 13:46 EST

Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026

KPTIKaryopharm Therapeutics2026-06-25 13:46 EST

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

KPTIKaryopharm Therapeutics2026-06-25 13:46 EST

Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation

KPTIKaryopharm Therapeutics2026-06-25 13:46 EST

Karyopharm to Participate at the 2026 Jefferies Global Healthcare Conference

KPTIKaryopharm Therapeutics2026-06-25 13:46 EST

Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment

KPTIKaryopharm Therapeutics2026-06-25 13:46 EST

Karyopharm to Participate at Upcoming Investor Conferences

KPTIKaryopharm Therapeutics2026-06-25 13:46 EST

Karyopharm to Report First Quarter 2026 Financial Results on May 14, 2026

KPTIKaryopharm Therapeutics2026-06-25 13:46 EST

Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress

KPTIKaryopharm Therapeutics2026-06-25 13:46 EST

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

View all latest news

Karyopharm Therapeutics

Karyopharm Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

KPTIKaryopharm Therapeutics2026-06-26 07:30 EST

Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026

KPTIKaryopharm Therapeutics2026-06-26 07:30 EST

Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026

KPTIKaryopharm Therapeutics2026-06-26 07:30 EST

Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology

KPTIKaryopharm Therapeutics2026-06-26 07:30 EST

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

KPTIKaryopharm Therapeutics2026-06-26 07:30 EST

Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States